Lundbeck Takes A Singular View Toward Tackling Challenging CNS Disorders
Executive Summary
The Danish drug maker has focused R&D on four CNS specialties under its new CEO and is moving forward two late-stage programs for symptoms of Alzheimer’s disease. Exec VP-Lundbeck Research, USA Stevin Zorn discusses the firm’s R&D strategy in an interview.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.